Stock Analysis
DexCom, Inc. (DXCM) Stock Analysis
DexCom, Inc. (DXCM) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
DexCom, Inc. (DXCM) currently has an AIQ Score of 53/100, indicating a neutral setup. Quality is the strongest factor at 86/100. Value is the weakest current factor at 28/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
DXCM at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $83.03 |
| AIQ Score | 53/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Sell |
| Market Cap | $34.02B |
| P/E Ratio | 35.35 |
| Forward P/E | — |
| EPS | $0.65 |
| Revenue TTM | $1.31B |
| Dividend Yield | 0.00% |
| Beta | 1.41 |
| Volume | 2.55M |
| 52-week range | $54.11-$92.59 |
| RSI 14 | 18.58 |
| 50-Day SMA | $82.41 |
| 200-Day SMA | $71.39 |
| Analyst Price Target | $87.68 |
| Next Earnings | Oct 29, 2026 |
DXCM
OverviewDXCM Stock Analysis Summary
DexCom, Inc. (DXCM) currently has an AIQ Score of 53/100, indicating a neutral setup. Quality is the strongest factor at 86/100. Value is the weakest current factor at 28/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, DXCM has AIQ Score of 53/100 with Quality base of 86/100 and fading Value at 28/100. Wait for component alignment before adding exposure.
Quality (86/100) leads while Value (28/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -1.75% stock move · DXCM classified in Medical - Devices.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is DXCM Bullish or Bearish Right Now?
DXCM currently has a neutral overall setup. Quality is the strongest factor at 86/100, while Value is weakest at 28/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 86/100.
- - Risk Resilience is supportive at 60/100.
- - Price is +0.75% above its 50-day SMA.
- - Analyst target implies +5.60% upside from the latest quote.
- - Value is the current constraint at 28/100.
- - Momentum is weak at 41/100.
- - Technical consensus has more sell votes than buy votes (26 vs 17).
Current Consensus
DXCM's Technical Analysis Consensus is currently Sell, with 17 buy, 2 neutral, and 26 sell votes. DXCM's 14-day RSI is 18.58, which places the stock in an oversold momentum range. DXCM's beta is 1.41, indicating greater market sensitivity than the broad market.
What Changed in DXCM?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the DXCM Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
DXCM Decision Framework
Public evidence layers, setup checks, and risk context for DexCom, Inc..
DexCom, Inc. (DXCM) Stock Analysis
DexCom, Inc. has an AIQ Score of 53/100 in a Neutral regime. Quality is strongest at 86/100. Beta is 1.41, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | DXCM is in a Neutral AIQ regime with score 53/100. |
| Signal Conflict | The primary conflict is that quality leads at 86/100 while value lags at 28/100. |
| Factor Evidence | Momentum 41/100 · Value 28/100 · Quality 86/100 · Risk 60/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 86/100.
Momentum is 41/100 and RSI (14) is 18.6.
DXCM is in a Neutral regime at 53/100.
Risk factor is 60/100 with beta 1.41 and annual volatility 41.18%.
Current conflict: quality leads at 86/100 while value lags at 28/100.
DXCM Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
DXCM Fundamentals
DXCM valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
DXCM Technical Analysis
DXCM technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
DXCM Stock Catalysts
Track DXCM earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
DXCM Dividend Analysis
DXCM dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
DXCM Financial Data
DXCM revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
DXCM Risk Analysis
DXCM volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
DXCM Stock News
DXCM stock news, market tone, recent headlines, and catalyst context.
DXCM vs Medical Devices Peers
Current peer cohort: DXCM · ENOV · EW · GEHC · GMED. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| DXCM Current stock | 53/100 | 28/100 | 41/100 | 60/100 | 0.33 | 41.18% | Current |
| ENOV Enovis Corporation | 47/100 | 74/100 | 24/100 | 40/100 | -0.47 | 63.37% | DXCM vs ENOV |
| EW Edwards Lifesciences | 46/100 | 28/100 | 23/100 | 77/100 | 0.27 | 25.38% | DXCM vs EW |
| GEHC GE HealthCare | 49/100 | 65/100 | 21/100 | 60/100 | -0.43 | 35.02% | DXCM vs GEHC |
| GMED Globus Medical | 54/100 | 55/100 | 21/100 | 75/100 | 0.63 | 48.96% | DXCM vs GMED |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching DXCM
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for DXCM
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
DXCM Stock FAQ
What is DXCM stock price today?
DexCom, Inc.'s current stock price is $83.03. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is DXCM bullish or bearish right now?
DXCM's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is DXCM's market cap?
DXCM's market cap is $34.02B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is DXCM's current P/E ratio?
DXCM's current P/E ratio is 35.35 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is DXCM's RSI?
DXCM's 14-day RSI is 18.58 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is DXCM above its 50-day and 200-day moving averages?
DXCM is 0.75% from its 50-day SMA and 16.31% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is DXCM's next earnings date?
DXCM's next earnings date is currently listed as Oct 29, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does DXCM pay a dividend?
DXCM's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.